Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[Association between norepinephrine combined with dopamine/dobutamine and 28-day death risk in patients with sepsis-induced myocardial injury: a pulse pressure-stratified study based on MIMIC-IV].

Created on 18 Nov 2026

Authors

Junyu Huang, Xingqi Wen, Jinghua Li, Haiyao Zhao, Jun He, Zilun Lin, Wenxing Huang, Minxuan Huang, Weiyan Chen

Published in

Zhonghua wei zhong bing ji jiu yi xue. Volume 38. Issue 10. Pages 905-915.

Abstract

To investigate the association between norepinephrine (NE) combined with dopamine (DA) or dobutamine (DBA) and the risk of 28-day death in patients with sepsis-induced myocardial injury (SIMI), and to examine whether this association varied across different pulse pressure (PP) levels.
A retrospective observational cohort study was conducted using the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Adult patients with sepsis who met the Sepsis-3 diagnostic criteria, had a first abnormal elevation in cardiac troponin T (cTnT; >0.01 μg/L), and had no other independent causes of myocardial injury were included. The time of the first abnormal cTnT elevation was defined as the index time point (T0), and the exposure window extended from 12 hours before T0 to 24 hours after T0. Patients were divided into an NE-alone group and an NE combined with DA/DBA group according to whether DA or DBA was administered in addition to NE during the exposure window. The primary outcome was 28-day all-cause death from T0. Cox proportional hazards models and propensity score matching (PSM) were used to evaluate the association between NE combined with DA/DBA and 28-day death risk. PP-stratified analyses, restricted cubic spline analyses, and treatment×PP interaction analyses were also performed. Sensitivity analyses were conducted using alternative PSM specifications and stabilized inverse probability of treatment weighting (IPTW).
A total of 1 155 patients with SIMI were included, of whom 991 received NE alone and 164 received NE combined with DA/DBA. After PSM, 306 patients were retained in the overall cohort. After stratified PSM, 176, 212, and 250 patients were retained in the PP<50 mmHg, PP<55 mmHg, and PP<60 mmHg (1 mmHg=0.133 kPa) strata, respectively. Before PSM, 28-day mortality was higher in the NE combined with DA/DBA group than in the NE-alone group in the overall cohort [50.6% (83/164) vs. 42.3% (419/991); hazard ratio (HR)=1.384, 95% confidence interval (95%CI) was 1.081-1.773, P=0.010]. After multivariable adjustment, the difference in 28-day death risk between the two groups was not statistically significant (HR=1.112, 95%CI was 0.750-1.650, P=0.596). After PSM, 28-day death risk did not differ significantly between the two groups [48.4% (74/153) vs. 46.4% (71/153); HR=1.044, 95%CI was 0.733-1.488, P=0.810]. In the PP<50 mmHg stratum, the risk of 28-day death in the NE combined with DA/DBA group was 1.6 fold higher than that in the NE-alone group before PSM (HR=1.598, 95%CI was 1.179-2.167, P=0.003), whereas no statistically significant difference was observed after PSM (HR=1.225, 95%CI was 0.819-1.832, P=0.324). The results were similar when using 55 mmHg and 60 mmHg as alternative cut-off points, with no statistically significant inter-group differences observed either after PSM in the low PP stratum or before and after PSM in each high PP stratum. No significant treatment×PP interaction was identified by restricted cubic spline analysis (P=0.821). No significant association between combined therapy and 28-day death risk was observed in analyses using alternative PSM specifications and stabilized IPTW.
After multivariable adjustment and PSM, no significant association was found between NE combined with DA/DBA and 28-day death risk in patients with SIMI. PP stratification did not identify a specific subgroup that benefited from NE combined with DA/DBA.

PMID:
43045521
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement